



107 College Road East  
 Princeton, NJ 08540  
 Tel: 609.608.1246  
 jcalvarez@drreddys.com

**VIA EMAIL – AGO.highcostprescriptiondrugs@vermont.gov**

September 16, 2019

Vermont Attorney General’s Office  
 109 State Street  
 Montpelier, VT 05609

**RE: New Prescription Drug – 30-Day Notice**

Dear Sir or Madam,

Dr. Reddy’s Laboratories, Inc. (“Dr. Reddy’s”) is providing this information in accordance with 18 V.S.A. § 4637(c), which requires that prescription drug manufacturers notify the Office of the Attorney General and to provide certain information following the release of a drug in the commercial market whose Wholesale Acquisition Cost (“WAC”) exceeds the threshold set for a specialty drug under the Medicare Part D Program.

NDC:	43598-0697-50
Product Description:	Vigabatrin for Oral Solution, USP 500 mg
Date of Introduction to Market:	08/19/2019
WAC:	\$3,652.94 per package of 50 packets
Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	Dr. Reddy’s does not believe this information is publicly available and has not released this information in the public domain.
The estimated volume of patients that may be prescribed the drug	Dr. Reddy’s does not believe this information is publicly available and has not released this information in the public domain.
Was the drug granted breakthrough therapy designation by the federal Food and Drug Administration (FDA) prior to final approval?	No
Did the drug receive a priority review by the federal Food and Drug Administration prior to final approval?	Yes
The date and price of acquisition if the drug was not developed by the manufacturer	N/A

Please do not hesitate to contact us if you have any questions.

Regards,

Juan Alvarez  
 Government Contracts & Pricing  
 Dr. Reddy’s Laboratories, Inc.